Cytokines as biomarkers in depressive disorder: Current standing and prospects

International Review of Psychiatry

Volumn 25, Issue 5, 2013, Pages 592-603

  Lichtblau, Nicole ^a,c   Schmidt, Frank M ^a   Schumann, Robert ^a,b   Kirkby, Kenneth C ^d   Himmerich, Hubertus ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c Schloss Werneck   (Germany)

^d UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; CELECOXIB; CYTOKINE; ETANERCEPT; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1BETA; MIRTAZAPINE; MONOAMINE; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CYTOKINE PRODUCTION; DEPRESSION; DISEASE COURSE; ENZYME ACTIVITY; GLIA CELL; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATION; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TREATMENT RESPONSE; VAGUS NERVE;

ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; CYTOKINES; DEPRESSIVE DISORDER; HUMANS;

EID: 84886699181     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.3109/09540261.2013.813442     Document Type: Article

References (125)

1. Abbasi, S.H., Hosseini, F., Modabbernia, A., Ashrafi, M. & Akhondzadeh, S. (2012). Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebocontrolled study. Journal of Affective Disorders, 141, 308-314.
2. Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A.A., Ghoreishi, A., Salehi, B., ? Kamalipour, A. (2009). Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial. Journal of Depression and Anxiety, 26, 607-611.
3. Antonioli, M., Rybka, J. & Carvalho, L.A. (2012). Neuroimmune endocrine effects of antidepressants. Neuropsychiatric Disease and Treatment, 8, 65-83.
4. Argaw, A.T., Asp, L., Zhang, J., Navrazhina, K., Pham, T., Mariani, J.N., ? John, G.R. (2012). Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. Journal of Clinical Investigation, 122, 2454-2468.
5. Banks, W.A. (2001). Anorectic effects of circulating cytokines: Role of the vascular blood-brain barrier. Nutrition, 17, 434-437.
6. Bano, S., Gitay, M., Ara, I. & Badawy, A. (2010). Acute effects of serotonergic antidepressants on tryptophan metabolism and corticosterone levels in rats. Pakistan Journal of Pharmaceutical Sciences, 23, 266-272.
7. Bano, S., Morgan, C.J., Badawy, A.A.B., Buckland, P.R. & McGuffin, P. (1999). Inhibition of rat liver tryptophan pyrrolase activity by fluoxetine. Pakistan Journal of Pharmaceutical Sciences , 12, 11-16.
8. Bauer, M., Adli, M., Bschor, T., Pilhatsch, M., Pfennig, A., Sasse, J., ? Lewitzka, U. (2010). Lithium ' s emerging role in the treatment of refractory major depressive episodes: Augmentation of antidepressants. Neuropsychobiology, 62, 36-42.
9. Baune, B.T., Dannlowski, U., Domschke, K., Janssen, D.G., Jordan, M.A., Ohrmann, P., ? Suslow T. (2010). The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression . Biological Psychiatry, 67, 543-549.
10. Belanoff, J.K., Rothschild, A.J., Cassidy, F., Debattista, C., Baulieu, E.E., Schold, C. & Schatzberg, A.F. (2002). An open label trial of C-1073 (mifepristone) for psychotic major depression . Biological Psychiatry, 52, 386-392.
11. Benedetti, F., Campori, E., Colombo, C. & Smeraldi, E. (2004). Fluvoxamine treatment of major depression associated with multiple sclerosis. Journal of Neuropsychiatry and Clinical Neurosciences, 16, 364-366.
12. Berthold-Losleben, M. & Himmerich, H. (2008). The TNFalpha system: Functional aspects in depression, narcolepsy and psychopharmacology. Current Neuropharmacology, 6, 193-202.
13. Besedovsky, H.O., del Rey, A., Klusman, I., Furukawa, H., Monge Arditi, G. & Kabiersch, A. (1991). Cytokines as modulators of the hypothalamus-pituitary-adrenal axis. Journal of Steroid Biochemistry and Molecular Biology, 40, 613-618.
14. Bluth é, R.M., Michaud, B., Kelley, K.W. & Dantzer, R. (1996). Vagotomy attenuates behavioural effects of interleukin-1 injected peripherally but not centrally. Neuroreport, 7, 1485-1488.
15. Bluth é, R.M., Walter, V., Parnet, P., Lay é, S., Lestage, J. & Verrier, D., ? Dantzer, R. (1994). Lipopolysaccharide induces sickness behaviour in rats by a vagal mediated mechanism. Comptes Rendus de l ' Acad é mie des Sciences, 317, 499-503.
16. Bromet, E., Andrade, L.H., Hwang, I., Sampson, N.A., Alonso, J., de Girolamo, G. ? Kessler, R.C. (2011). Crossnational epidemiology of DSM-IV major depressive episode. BMC Medicine, 9, 90.
17. Capuron, L. & Miller, A.H. (2011). Immune system to brain signaling: Neuropsychopharmacological implications. Pharmacology and Therapeutics, 130, 226-238.
18. Carpenter, L.L., Heninger, G.R., Malison, R.T., Tyrka, A.R. & Price, L.H. (2004). Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. Journal of Affective Disorders, 79, 285-289.
19. Chang, H.D. & Radbruch, A. (2007). The pro-and anti-inflammatory potential of interleukin-12. Annals of the New York Academy of Sciences, 1109, 40-46.
20. Chiaravalloti, N.D. & Deluca, J. (2008). Cognitive impairment in multiple sclerosis. Lancet Neurology, 7, 1139-1151.
21. da Silva, A.M., Vilhena, E., Lopes, A., Santos, E., Gon ç alves, M.A., Pinto C.,. Cavaco, S. (2011). Depression and anxiety in a Portuguese MS population: Associations with physical disability and severity of disease. Journal of the Neurological Sciences, 306, 66-70.
22. Dantzer, R. (2009). Cytokine, sickness behavior, and depression. Immunology and Allergy Clinics of North America, 29, 247-264.
23. Di Costanzo, L., Ayala, F., Megna, M., Gaudiello, F., Patr ì, A. & Balato. N. (2013). The risk of herpes zoster in the anti-TNF-era: A case report and review of the literature. Journal of Dermatology Case Reports, 7, 1-4.
24. Domingues, H.S., Mues, M., Lassmann, H., Wekerle, H. & Krishnamoorthy, G. (2010). Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. PLoS One, 5, 15531.
25. Eller, T., Aluoja, A., Maron, E. & Vasar, V. (2009). Soluble interleukin-2 receptor and tumor necrosis factor levels in depressed patients in Estonia. Medicina (Kaunas), 45, 971-977.
26. Eller, T., Vasar, V., Shlik, J. & Maron, E. (2008) Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32, 445-450.
27. Erhardt, S., Lim, C.K., Linderholm, K.R., Janelidze, S., Lindqvist, D., Samuelsson, M., ? Brundin, L. (2013). Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology, 38, 743-752.
28. Ericsson, A., Kovacs, K.J. & Sawchenko, P.E. (1994). A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. Journal of Neuroscience, 14, 897-913.
29. Feinstein, A. (2000). Multiple sclerosis, disease modifying treatments and depression: A critical methodological review. Multiple Sclerosis Journal, 6, 343-348.
30. Feinstein, A. (2004). The neuropsychiatry of multiple sclerosis. Canadian Journal of Psychiatry, 49, 157-163.
31. Feinstein, A., O ' Connor, P. & Feinstein, K. (2002). Multiple sclerosis, interferon beta-1b and depression: A prospective investigation . Journal of Neurology, 249, 815-820.
32. Fluitman, S.B., Heijnen, C.J., Denys, D.A., Nolen, W.A., Balk, F.J. & Westenberg, H.G. (2011). Electroconvulsive therapy has acute immunological and neuroendocrine effects in patients with major depressive disorder. Journal of Affective Disorders, 131, 388-392.
33. Foley, F.W., Traugott, U., La Rocca, N.G., Smith, C.R., Perlman, K.R., Caruso, L.S. & Scheinberg, L.C. (1992). A prospective study of depression and immune dysregulation in multiple sclerosis. Archives of Neurology, 49, 238-244.
34. Fuchs, E. & Flü gge, G. (2005). Eine St ö rung der Neuroplastizit ä t? [A disorder of neuroplasticity?] Psychoneuroimmunologie, 31, 197-203.
35. Gill, J., Luckenbaugh, D., Charney, D. & Vythilingam, M. (2010). Sustained elevation of serum interleukin-6 and relative insensitivity to hydrocortisone differentiates posttraumatic stress disorder with and without depression. Biological Psychiatry , 68, 999-1006.
36. Girgenti, M.J., Hunsberger, J., Duman, C.H., Sathyanesan, M., Terwilliger, R. & Newton, S.S. (2009). Erythropoietin induction by electroconvulsive seizure, gene regulation, and antidepressant-like behavioral effects. Biological Psychiatry, 66, 267-274.
37. Goldman Consensus Group. (2005). The Goldman Consensus statement on depression in multiple sclerosis. Multiple Sclerosis Journal, 11, 328-337.
38. Halperin, D. & Reber, G. (2007). Influence of antidepressants on hemostasis. Dialogues in Clinical Neuroscience, 9, 47-59.
39. Heiser, P., Lanquillon, S., Krieg, J.C. & Vedder, H. (2008). Differential modulation of cytokine production in major depressive disorder by cortisol and dexamethasone. European Neuropsychopharmacology, 18, 860-870.
40. Himmerich, H., Berthold-Losleben, M. & Pollmächer, T. (2009). The relevance of the TNF-alpha system in psychiatric disorders. Fortschritte der Neurologie-Psychiatrie, 77, 334-345.
41. Himmerich, H., Fulda, S., Linseisen, J., Seiler, H., Wolfram, G., Himmerich S., ? Pollm ä cher, T. (2008). Depression, comorbidities and the TNF-alpha system. European Psychiatry, 23, 421-429.
42. Himmerich, H., Fulda, S., Sheldrick, A.J., Pl ü m ä kers, B. & Rink, L. (2010b). IFN-gamma reduction by tricyclic antidepressants . International Journal of Psychiatry in Medicine, 40, 413-424.
43. Himmerich, H., Koethe, D., Schuld, A., Yassouridis, A. & Pollm ä cher, T. (2005). Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. Psychopharmacology, 179, 447-451.
44. Himmerich, H., Milenovi ć, S., Fulda, S., Pl ü m ä kers, B., Sheldrick, A.J., Michel, T.M., ? Rink, L. (2010a). Regulatory T cells increased while IL-1 decreased during antidepressant therapy. Journal of Psychiatric Research, 44, 1052-1057.
45. Himmerich, H. & Sheldrick, A.J. (2010). TNF-alpha and ghrelin: Opposite effects on immune system, metabolism and mental health. Protein and Peptide Letters, 17, 186-196.
46. Himmerich, H., Sorge, S., Kirkby, K.C. & Steinberg, H. (2012). Schizophrenic disorders. The development of immunological concepts and therapy in psychiatry. Nervenarzt, 83, 7-15.
47. Himmerich, H. & Wranik, D.W. (2012). Choice of treatment with antidepressants: Influencing factors. Current Pharmaceutical Design, 18, 5958-5975.
48. Hinze-Selch, D., Schuld, A., Kraus, T., Kü hn, M., Uhr, M., Haack, M. & Pollm ä cher T (2000). Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology, 23, 13-19.
49. Janelidze, S., Ventorp, F., Erhardt, S., Hansson, O., Minthon, L. Flax, J., ? Brundin, L. (2012). Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters. Psychoneuroendocrinology. doi: 10.1016/j.psyneuen.2012.09.010
50. Joffe, R.T., Lippert, G.P., Gray, T.A., Sawa, G. & Horwath, Z. (1987). Mood disorders and multiple sclerosis. Archives of Neurology, 44, 376-378.
51. Jokinen, J., Chatzittofis, A., Hellstr ö m, C., Nordstr ö m, P., Uvn ä s-Moberg, K. & Asberg, M. (2012). Low CSF oxytocin reflects high intent in suicide attempters. Psychoneuroendocrinology , 37, 482-490.
52. Kawaguchi, R., Shimokawa, T., Umehara, N., Nunomura, S., Tanaka, T. & Ra, C. (2008). Priming of peripheral monocytes with prolactin (PRL) sensitizes IFN-gamma-mediated indoleamine 2,3-dioxygenase (IDO) expression without affecting IFN-gamma signaling. Journal of Reproductive Immunology, 77, 117-125.
53. Khosro, S., Alireza, S., Omid, A. & Forough, S. (2011). Night work and inflammatory markers. Indian Journal of Occupational and Environmental Medicine, 15, 38-41.
54. Kiank, C., Zeden, J.P., Drude, S., Domanska, G., Fusch, G., Otten, W. & Schuett, C. (2010). Psychological stress-induced, IDO1-dependent tryptophan catabolism: Implications on immunosuppression in mice and humans. PLoS One, 5, e11825.
55. Kim, Y.K., Na, K.S., Shin, K.H., Jung, H.Y., Choi, S.H. & Kim, J.B. (2007). Cytokine imbalance in the pathophysiology of major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31, 1044-1033.
56. Koch, M.W., Glazenborg, A., Uyttenboogaart, M., Mostert, J. & De Keyser, J. (2011). Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database of Systematic Reviews, CD007295.
57. Kraus, T., Haack, M., Schuld, A., Hinze-Selch, D., Koethe, D. & Pollm ä cher, T. (2002). Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry, 35, 220-225.
58. Kr ü gel, U., Fischer, J., Radicke, S., Sack, U. & Himmerich, H. (2013). Antidepressant effects of TNF-blockade in an animal model of depression. Journal of Psychiatric Research, 47, 611-616.
59. Kuhn R. (1958). The treatment of depressive states with G 22355 (imipramine hydrochloride). American Journal of Psychiatry, 115, 459-464.
60. Lanquillon, S., Krieg, J.-C., Bening-Abu-Shach, U. & Vedder, H. (2000). Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology, 22, 370-379.
61. Leucht, C., Huhn, M., Leucht, S. (2012). Amitriptyline versus placebo for major depressive disorder. Cochrane Database of Systematic Reviews, CD009138.
62. Li, X., Cudaback, E., Breyer, R.M., Montine, K.S., Keene, C.D. & Montine, T.J. (2012). Eicosanoid receptor subtype-mediated opposing regulation of TLR-stimulated expression of astrocyte glial-derived neurotrophic factor. FASEB Journal, 26, 3075-3083.
63. Lichtblau, N., Schmidt, F. & Himmerich, H. (2012). Die Rolle von Zytokinen bei psychiatrischen Erkrankungen-Immunsystem und Depression [Influences of cytokines on psychiatric disorders-the immune system and depression]. InFo Neurologie Psychiatrie, 14, 56-62.
64. Lindqvist, D., Janelidze, S., Erhardt, S., Tr ä skman-Bendz, L., Engstr ö m, G. & Brundin, L. (2011). CSF biomarkers in suicide attempters-A principal component analysis. Acta Psychiatrica Scandinavica, 124, 52-61.
65. Lindqvist, D., Janelidze, S., Hagell, P., Erhardt, S., Samuelsson, M., Minthon, L., ? Brudin, L. (2009). Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biological Psychiatry, 66, 287-292.
66. Ljung, L., Smeds, J., Persson, G., Jirl é n, L. & Toolanen, G. (2012). Immunosuppression may mask severe infection. Septic arthritis in tocilizumab treatment yielded only modest acute-phase reaction. Lakartidningen, 109, 1678-1679.
67. Loser, K. & Beissert, S. (2007). Dendritic cells and T cells in the regulation of cutaneous immunity. Advances in Dermatology, 23, 307-333.
68. Lotrich F. (2012). Inflammatory cytokines, growth factors, and depression. Current Pharmaceutical Design, 18, 5920-5935.
69. Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E. & Neels, H. (1997). Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine, 9, 853-858.
70. Maes, M., Meltzer, H.Y., Bosmans, E., Bergmans, R., Vandoolaeghe , E., Ranjan, R & Desnyder, R. (1995). Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. Journal of Affective Disorders, 34, 301-309.
71. Malynn, S., Campos-Torres, A., Moynagh, P. & Haase, J. (2013). The pro-inflammatory cytokine TNF-regulates the activity and expression of the serotonin transporter (SERT) in astrocytes . Neurochemical Research, 38, 694-704.
72. Martinez, J.M., Garakani, A., Yehuda, R. & Gorman, J.M. (2012). Proinflammatory and ' resiliency ' proteins in the CSF of patients with major depression. Depression and Anxiety, 29, 32-38.
73. Mattox, J.H., Buckman, M.T., Bernstein, J., Pathak, D. & Kellner, R. (1986). Dopamine agonists for reducing depression associated with hyperprolactinemia. Journal of Reproductive Medicine, 31, 694-698.
74. McIvor, G.P., Riklan, M. & Reznikoff, M. (1984). Depression in multiple sclerosis as a function of length and severity of illness, age, remission and perceived social support. Journal of Clinical Psychology, 40, 1028-1033.
75. Mendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S. & Brunello, N. (2006). Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: A pilot open-label study. International Clinical Psychopharmacology, 21, 227-231.
76. Merrill, J.E. (1992). Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological . Developmental Neuroscience, 14, 1-10.
77. Mitsonis, C.I., Zervas, I.M., Potagas, C.M., Mitropoulos, P.A., Dimopoulos, N.P., Sfagos, C.A. ? Vassilopoulos, D.C. (2010). Effects of escitalopram on stress-related relapses in women with multiple sclerosis: An open-label, randomized, controlled, one-year follow-up study. European Neuropsychopharmacology , 20, 123-131.
78. Modabbernia, A., Taslimi, S., Brietzke, E. & Ashrafi, M. (2013). Cytokine alterations in bipolar disorder: A meta-analysis of 30 studies. Biological Psychiatry. doi: 10.1016/j.biopsych.2013. 01.007
79. Mohr, D.C., Boudewyn, A.C., Goodkin, D.E., Bostrom, A. & Epstein, L. (2001). Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. Journal of Consulting and Clinical Psychology, 69, 942-949.
80. Mohr, D.C., Hart, S.L., Fonavera, I. & Tasch, E.S. (2006). Treatment of depression for patients with multiple sclerosis in neurology clinics. Multiple Sclerosis Journal, 12, 204-208.
81. Mohr, D.C., Hart, S.L., Julian, L., Catledge, C., Honos-Webb, L., Vella, L. & Tasch, E.T. (2005). Telephone-administered psychotherapy for depression. Archives of General Psychiatry, 62, 1007-1014.
82. Mostert, J.P., Admiraal-Behloul, F., Hoogduin, J.M., Luyendijk, J., Heersema, D.J., van Buchem, M.A. & De Keyser, J. (2008). Effects of fluoxetine on disease activity in relapsing multiple sclerosis: A double-blind, placebo-controlled, exploratory study. Journal of Neurology, Neurosurgery and Psychiatry, 79, 1027-1031.
83. M ü ller, N. & Schwarz, M.J. (2007). Immunologische Aspekte bei depressiven St ö rungen [Immunological aspects of depressive disorders]. Nervenarzt, 78, 1261-1273.
84. M ü ller, N., Schwarz, M.J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-M ü ller, B., ? Riedel, M. (2006). The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Molecular Psychiatry, 11, 680-684.
85. Musgrave, T., Benson, C., Wong, G., Browne, I., Tenorio, G., Rauw, G., ? Kerr, B.J. (2011). The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain, Behavior, and Immunity, 25, 1677-1688.
86. Nakata, A., Haratani, T., Takahashi, M., Kawakami, N., Arito, H., Kobayashi F.,. Araki, S. (2004). Association of sickness absence with poor sleep and depressive symptoms in shift workers. Chronobiology International, 21, 899-912.
87. P å lhagen, S., Qi, H., Må rtensson, B., Wå linder, J., Gran é rus, A.K. & Svenningsson, P. (2010). Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson ' s disease and major depression. Journal of Neurology, 257, 524-532.
88. Pandey, G.N., Rizavi, H.S., Ren, X., Fareed, J., Hoppensteadt, D.A., Roberts, R.C., ? Dwivedi, Y. (2011). Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. Journal of Psychiatric Research, 46, 57-63.
89. Patten, S.B., Williams, J.V. & Love, E.J. (1995). A case-control study of corticosteroid exposure as a risk factor for clinicallydiagnosed depressive disorders in a hospitalized population. Canadian Journal of Psychiatry, 40, 396-400.
90. Peck, A. & Mallins, E.D. (2009). Plasticity of T-cell phenotype and function: The Thelper type 17 example. Immunology, 129, 147-153.
91. Penninx, B.W., Kritchevsky, S.B., Yaffe, K., Newman, A.B., Simonsick, E.M., Rubin, S., ? Pahor, M. (2003). Inflammatory markers and depressed mood in older persons: Results from the Health, Aging and Body Composition study. Biological Psychiatry, 54, 566-572.
92. Pincus, H.A. & Pettit, A.R. (2001) The societal costs of chronic major depression. Journal of Clinical Psychiatry, 62(S6), S5-9.
93. Price, A., Rayner, L., Okon-Rocha, E., Evans, A., Valsraj, K., Higginson, I.J. & Hotopf, M. (2011). Antidepressants for the treatment of depression in neurological disorders: A systematic review and meta-analysis of randomised controlled trials. Journal of Neurology, Neurosurgery and Psychiatry, 82, 914-923.
94. Ramamoorthy, S., Ramamoorthy, J.D., Prasad, P.D., Bhat, G.K., Mahesh, V.B., Leibach, F.H. & Ganapathy, V. (1995). Regulation of the human serotonin transporter by interleukin-1 beta. Biochemical and Biophysical Research Communications, 216, 560-567.
95. Rief, W., Mills, P.J., Ancoli-Israel, S., Ziegler, M.G., Pung, M.A. & Dimsdale, J.E. (2010). Overnight changes of immune parameters and catecholamines are associated with mood and stress. Psychosomatic Medicine, 72, 755-762.
96. Rivera-Baltanas, T., Olivares, J.M., Calado-Otero, M., Kalynchuk, L.E., Martinez-Villamarin, J.R. & Caruncho, H.J. (2012). Serotonin transporter clustering in blood lymphocytes as a putative biomarker of therapeutic efficacy in major depressive disorder. Journal of Affective Disorders, 137, 46-55.
97. Rothermundt, M., Arolt, V., Fenker, J., Gutbrodt, H., Peters, M. & Kirchner, H. (2001). Different immune patterns in melancholic and non-melancholic major depression. European Archives of Psychiatry and Clinical Neurosciences, 251, 90-97.
98. Sasayama, D., Hattori, K., Wakabayashi, C., Teraishi, T., Hori, H., Ota, M., ? Kunugi, H. (2013). Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. Journal of Psychiatric Research, 47, 401-406.
99. Schildkraut, J.J. (1965). The catecholamine hypothesis of affective disorders: A review of supporting evidence. American Journal of Psychiatry, 122, 509-522.
100. Schumann, R., Adamaszek, M., Sommer, N. & Kirkby, K.C. (2012). Stress, depression and antidepressant treatment options in patients suffering from multiple sclerosis. Current Pharmaceutical Design, 18, 5837-5845.
101. Scott, T.F., Nussbaum, P., McConnell, H. & Brill, P. (1995). Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Journal of Neurology Research, 17, 421-422.
102. Sijens, P.E., Mostert, J.P., Irwan, R., Potze, J.H., Oudkerk, M. & De Keyser, J. (2008). Impact of fluoxetine on the human brain in multiple sclerosis as quantified by proton magnetic resonance spectroscopy and diffusion tensor imaging. Psychiatry Research, 164, 274-282.
103. Slaughter, J.R., Slaughter, K.A., Nichols, D., Holmes, S.E. & Martens, M.P. (2001). Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson ' s disease. Journal of Neuropsychiatry and Clinical Neurosciences, 13, 187-196.
104. Sokero, T.P., Melartin, T.K., Ryts ä l ä, H.J., Leskel ä, U.S., Lestel ä-Mielonen, P.S. & Isomets ä, E.T. (2003). Suicidal ideation and attempts among psychiatric patients with major depressive disorder. Journal of Clinical Psychiatry, 64, 1094-1100.
105. Steinberg, H. & Himmerich, H. (2012). Roland Kuhn-100th birthday of an innovator of clinical psychopharmacology. Psychopharmacology Bulletin, 45, 48-50.
106. Su, S., Miller, A.H., Snieder, H., Bremner, J.D., Ritchie, J., Maisano, C., ? Vaccarino, V. (2009). Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged men: The Twins Heart Study. Psychosomatic Medicine , 71, 152-158.
107. Surget, A., Wang, Y., Leman, S., Ibarguen-Vargas, Y., Edgar, N., Griebel, G., ? Sibille, E. (2009). Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. Neuropsychopharmacology , 34, 1363-1380.
108. Surridge, D. (1969). An investigation into some psychiatric aspects of multiple sclerosis. British Journal of Psychiatry, 115, 749-764.
109. Taler, M., Gil-Ad, I., Korob, I. & Weizman, A. (2011). The immunomodulatory effect of the antidepressant sertraline in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Neuroimmunomodulation, 18, 117-122.
110. Thomas, A.J., Davis, S., Morris, C., Jackson, E., Harrison, R. & O ' Brien, J.T. (2005). Increase in interleukin-1beta in late-life depression. American Journal of Psychiatry, 162, 175-177.
111. Toh, S., Li, L., Harrold, L.R., Bayliss, E.A., Curtis, J.R., Liu, L., ? Herrinton, L.J. (2012). Comparative safety of infliximab and etanercept on the risk of serious infections: Does the association vary by patient characteristics? Pharmacoepidemiology and Drug Safety, 21, 524-534.
112. Tonelli, L.H., Stiller, J., Rujescu, D., Giegling, I., Schneider, B., Maurer, K., ? Postolache, T.T. (2008). Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatrica Scandinavica, 117, 198-206.
113. Tsai, S.J. (2007). Glatiramer acetate could be a potential antidepressant through its neuroprotective and anti-inflammatory effects. Medical Hypotheses, 69, 145-148.
114. Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., ? Krishnan, R. (2006). Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Doubleblind placebo-controlled randomised phase III trial. Lancet, 367, 29-35.
115. Tzartos, J.S., Friese, M.A., Craner, M.J., Palace, J., Newcombe, J., Esiri, M.M. & Fugger, L. (2008). Interleukin-17 production in central nervous system-infiltrating T Cells and glial cells is associated with active disease in multiple sclerosis. American Journal of Pathology, 172, 146-155.
116. van Haelst, I.M., Egberts, T.C., Doodeman, H.J., Traast, H.S., Burger, B.J., Kalkman, C.J. & van Klei, W.A. (2010). Use of serotonergic antidepressants and bleeding risk in orthopedic patients. Anesthesiology, 112, 631-636.
117. Vgontzas, A.N., Zoumakis, E., Bixler, E.O., Lin, H.M., Follett, H., Kales, A. & Chrousos, G.P. (2004). Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. Journal of Clinical Endocrinology and Metabolism, 89, 2119-2126.
118. Vignali, D.A., Collison, L.W. & Workman, C.J. (2008). How regulatory T cells work. Nature Reviews Immunology, 8, 523-532.
119. Vollmar, P., Nessler, S., Kalluri, S.R., Hartung, H.P. & Hemmer, B. (2009). The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. International Journal of Neuropsychopharmacology, 12, 525-536.
120. Waehrens, J. & Gerlach, J. (1981). Bromocriptine and imipramine in endogenous depression. A double-blind controlled trial in out-patients. Journal of Affective Disorders, 3, 193-202.
121. Warner-Schmidt, J.L., Vanover, K.E., Chen, E.Y., Marshall, J.J. & Greengard, P. (2011). Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proceedings of the National Academy of Sciences of the United States of America, 108, 9262-9267.
122. Watanabe, N., Omori, I.M., Nakagawa, A., Cipriani, A., Barbui, C., Churchill, R. & Furukawa, T.A. (2011). Mirtazapine versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews, CD006528.
123. Weschenfelder, J., Sander, C., Kluge, M., Kirkby, K.C. & Himmerich, H. (2012). The influence of cytokines on wakefulness regulation: clinical relevance, mechanisms and methodological problems. Psychiatria Danubina, 24, 112-126.
124. Yang, L., Zhang, Z., Sun, D., Xu, Z., Zhang, X. & Li, L. (2010). The serum interleukin-18 is a potential marker for development of post-stroke depression. Journal of Neurology Research, 32, 340-346.
125. Yoshimura, R., Hori, H., Ikenouchi-Sugita, A., Umene-Nakano, W., Ueda, N. & Nakamura, J. (2009). Higher plasma interleukin-6 (IL-6) level is associated with SSRI-or SNRI-refractory depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33, 722-726.